Sector authority · Manufacturing in India
Pharma and Medical Device Manufacturing in India: Where Regulation Decides the Answer
In regulated manufacturing the India decision is not primarily an economics decision. The regulatory pathway, the market you intend to supply and the maturity of your quality system determine what is possible; economics then determines whether it is worth doing.
This page is the sector view for pharmaceutical, API and medical-device manufacturers. It is manufacturing strategy, not regulatory or legal advice.
Sector authority · Manufacturing in IndiaWritten by NirjiX Manufacturing AdvisoryReviewed by Reviewed by the NirjiX Manufacturing practice, which advises global OEMs, GCC operators and PE portfolio companies on India manufacturing strategy, site selection and factory execution.Published January 2026Last reviewed February 202614 min read
Direct answer
Should a pharma or medical device company manufacture in India?
India is one of the strongest locations in the world for pharmaceutical and device manufacturing on capability and cost, and the decision usually turns on three questions rather than on the country itself. First, which markets the site will supply — a site serving highly regulated export markets must be designed, staffed and documented for those inspections from the outset, and retrofitting that standard later is expensive. Second, product criticality and regulatory class — a sterile injectable, an implantable device and a Class A device carry very different facility, validation and quality-system burdens. Third, whether your organisation can operate a quality system at distance, because the most common failure in this sector is governance, not capability. Where those three are addressed deliberately, India offers depth in formulations, APIs, contract manufacturing and a growing device base; where they are treated as execution detail, the project stalls at validation or at the first inspection.
Executive summary
- The target market decides the facility. Design to the standard of the most demanding market the site will ever supply — upgrading a facility and its documentation after approval is materially harder than building to standard once.
- Contract manufacturing is a legitimate strategic route in this sector, not just a stopgap: India's CDMO and contract device manufacturing base is deep, and a well-governed partner can reach approved supply faster than a greenfield site.
- Quality-system governance is the real risk, not capability. Data integrity, change control, deviation management and documentation discipline are what inspections examine, and they are organisational commitments rather than equipment purchases.
- Validation and qualification set the schedule. Facility, utility, equipment, process and analytical-method qualification run in a defined sequence, and the regulatory approval calendar is downstream of all of it.
- For devices, the classification and the intended market drive everything from cleanroom class to design-control documentation, and a strategy that averages across the portfolio will over-build for some products and under-build for others.
Five conclusions for a life-sciences board evaluating India manufacturing.
Why India fits life sciences — and when it does not
India's pharmaceutical manufacturing base is genuinely deep: formulations, APIs and intermediates, a large qualified workforce of chemists, microbiologists, quality professionals and validation engineers, an established contract manufacturing sector, and a supply base for utilities, cleanroom construction and validation services that exists precisely because the industry is large. For medical devices the base is younger but developing, with policy attention and dedicated device parks intended to build cluster infrastructure.
The cost position is real but secondary. What usually justifies India in this sector is the combination of qualified capacity, the availability of experienced regulatory and quality professionals, and the ability to run both domestic supply and export supply from the same base — provided the site is designed for the more demanding of the two.
India does not fit when the product's regulatory pathway makes a site change prohibitively expensive — a marketed product whose approval is tied to a specific site, with variation filings across many markets, may cost more to transfer than the manufacturing saving justifies. It also does not fit when the parent organisation cannot supply the quality-system oversight the site will require, or when volumes are too low to sustain the fixed cost of a compliant regulated facility. Novel processes, biologics at small scale, or products dependent on a single specialised material supplier outside India warrant particular caution.
Scope: which activities localise well, and what that requires
Regulated manufacturing scope is defined by facility class and validation burden rather than by cost.
| Activity | India fit | Principal requirement | Note |
|---|---|---|---|
| Oral solid dose formulations | Strong | GMP facility design, validation, documentation discipline | Deep domestic capability and contract capacity |
| APIs and intermediates | Strong | Process safety, effluent treatment, solvent handling, environmental consents | Site selection is heavily influenced by effluent and utility infrastructure |
| Sterile and injectable products | Selective | Aseptic facility design, environmental monitoring, personnel discipline | Highest facility and quality-system burden; partner selection matters most here |
| Biologics | Case by case | Specialised facilities, cold chain, analytical capability, technology transfer | Feasible but requires a deliberate technology-transfer programme |
| Medical devices — lower-risk classes | Strong | Quality management system, cleanroom where applicable, supplier control | Fastest device entry route, often with a contract manufacturer |
| Medical devices — higher-risk and implantable | Selective | Design control, biocompatibility, sterilisation validation, traceability | Requires mature quality systems and a longer approval calendar |
| Diagnostics and equipment | Growing | Electronics supply chain, software validation, service network | Overlaps with the electronics sector page for supply-chain planning |
The NirjiX sector framework
A sector adaptation of the NirjiX India Manufacturing Decision Framework for regulated products. It tests the conditions that determine whether an India site can be approved and sustained, before economics are modelled.
NirjiX Regulated Manufacturing Readiness Test
- 01
Market and standard definition
Name every market the site will supply now and later, and design to the most demanding inspection standard among them.
- 02
Product classification and facility class
Translate regulatory classification into facility class, environmental control, segregation and validation burden before any site is shortlisted.
- 03
Quality-system governance
Establish who owns the quality system, how data integrity is assured, and how deviations and change control are escalated to the parent. This is a governance decision, not a staffing one.
- 04
Technology transfer and validation plan
Define process transfer, analytical method transfer, validation batches and stability requirements, with realistic calendar time for each.
- 05
Supplier and material qualification
Qualify raw material, excipient, component and packaging suppliers, including change-notification obligations that survive the launch.
- 06
Inspection readiness as a run-state capability
Treat inspection readiness as continuous — documentation, training records and audit trails maintained as an operating discipline rather than assembled before a visit.
Fail any of the first three and the economics do not matter. Pass them and the remaining risk is manageable with disciplined execution.
The business case for regulated manufacturing in India
Applied to life sciences, the NirjiX India Manufacturing Business Case Framework carries lines that do not appear in other sectors: qualification and validation cost, stability and analytical programme cost, regulatory filing and variation cost, and the cost of maintaining inspection readiness continuously. These are not overheads to be trimmed; they are the cost of being allowed to supply.
Capital cost is driven by facility class rather than by floor area. Cleanroom classification, air handling, water systems, segregation, material and personnel flow, and environmental monitoring determine the majority of the build cost, and they are decided by the product and the target market, not by the budget. For API and chemical processing, effluent treatment and solvent management can rival process equipment in cost and dominate site selection.
The timeline carries its own economics. Between construction completion and approved commercial supply lie qualification, validation batches, stability data and regulatory review. That interval is real, it varies by market and product, and financing it is part of the case. Business cases that treat approval as an event rather than a phase understate working capital and overstate the return.
Where the case usually wins is in sustained cost position and capacity access once approved, plus the option value of supplying multiple markets from one qualified base. Where it usually loses is on transfer economics for an already-marketed product with a wide filing footprint.
Which Indian clusters fit pharma and device manufacturing?
In this sector, location is decided by regulatory-quality talent, utility and effluent infrastructure, and the presence of an existing regulated manufacturing base — not by land cost.
| Cluster | Character | Best fit | Watch |
|---|---|---|---|
| Hyderabad and Telangana | Deep pharma and API base, quality and regulatory talent, established supplier services | APIs, formulations, contract manufacturing, R&D-linked production | Water security, effluent capacity, competition for experienced QA staff |
| Gujarat (Ahmedabad–Vadodara–Ankleshwar belt) | Chemicals and API depth, effluent infrastructure, approval throughput, port access | APIs, intermediates, chemical-intensive processes | Environmental compliance scrutiny, solvent handling infrastructure |
| Maharashtra (Mumbai–Pune–Aurangabad) | Formulations, devices, regulatory and commercial infrastructure | Formulations, devices, export-facing operations | Land cost, utility reliability at specific sites |
| Himachal Pradesh and Uttarakhand belts | Established formulation manufacturing clusters | Domestic-market formulations and contract manufacturing | Logistics distance, talent availability for senior quality roles |
| Tamil Nadu and Chennai belt | Device manufacturing base, engineering supply chain, port access | Medical devices, diagnostics, equipment assembly | Cleanroom construction capacity, specialised component supply |
| Dedicated medical-device parks | Purpose-built infrastructure with common facilities where operational | Device manufacturers seeking utility and testing infrastructure | Verify which common facilities are operational, not merely announced |
Incentives and policy relevant to pharma and devices
- Production Linked Incentive schemes for pharmaceuticals — organised by product category with investment, production and timeline conditions defined in scheme guidelines.
- Production Linked Incentive scheme for medical devices — targeted at specified device segments, with capacity and investment conditions.
- Bulk drug park and medical device park programmes — infrastructure-led support where the value is common utilities, effluent treatment and testing facilities rather than a cash incentive; verify what is operational at the specific park.
- State pharmaceutical, life-science and industrial policies — capital subsidy, utility and effluent infrastructure support, stamp duty and electricity duty treatment, and assistance tied to employment or investment.
- Import duty treatment of APIs, excipients, components and capital equipment, which affects landed cost and should be modelled by classification.
- Realisation discipline — regulated-sector claims must reconcile with production records and regulatory filings, so incentive claim design should be reviewed alongside the quality and ERP configuration, not after it.
Structures as published by the administering authority; eligibility, quantum and conditions change by notification and must be confirmed at application.
Own site, CDMO, JV or acquisition?
In regulated manufacturing, the operating-model choice is largely a choice about who carries regulatory accountability and how fast approved supply is needed.
| Model | Fits when | Main risk | Regulatory accountability |
|---|---|---|---|
| Own greenfield site | Long-term strategic supply, proprietary process, portfolio scale justifies fixed cost | Longest path to approved supply; full inspection exposure | Entirely yours |
| CDMO / contract manufacturing | Speed to approved supply, variable volume, capital discipline | Capacity priority, partner's compliance history becomes your risk | Shared; your oversight obligations remain |
| Acquisition of an approved site | Immediate approved capacity and trained staff are the objective | Inherited compliance history, remediation cost, data-integrity legacy | Yours from day one, including the history |
| Joint venture | Local market access or complementary capability matters | Governance of quality decisions across two organisations | Must be contractually explicit or it becomes the failure point |
| Hybrid: CDMO now, own site later | Market entry precedes volume certainty | Site transfer requires re-validation and regulatory variation | Plan the transfer cost at entry, not at exit |
Materials, suppliers and qualification
Material qualification in this sector is a regulatory activity, not only a commercial one. Raw materials, excipients, packaging components and device components must be qualified, and supplier changes carry notification and, in some cases, filing obligations. That makes dual sourcing harder and slower than in other industries, and it means supplier strategy must be designed with the regulatory affairs function rather than handed to procurement.
India's advantage is the availability of qualified domestic suppliers for many pharmaceutical inputs and an established local service base for validation, calibration, cleanroom construction and testing. The exposure lies in specific starting materials, specialised excipients, device-grade polymers, electronics and sterilisation services, which may be concentrated or imported.
Sterilisation, testing and calibration capacity deserve explicit planning for device manufacturers. Access to validated sterilisation and accredited testing on a reliable schedule shapes both site selection and inventory strategy, and it is a common late discovery in device projects.
Quality organisation and operating capability
- A quality head with genuine authority to stop production — organisational independence is what inspections test, and a reporting line that undermines it is a finding waiting to happen.
- Quality assurance and quality control depth: documentation, batch review, analytical capability, environmental monitoring and stability programme management.
- Validation and qualification engineering, including computer-system validation and data-integrity controls across the equipment estate.
- Regulatory affairs capability able to manage filings, variations and inspection correspondence for the target markets.
- Production leadership experienced in the specific facility class — aseptic operations in particular are a discipline, not a job description.
- Training systems that are demonstrable: training records, competency verification and change-driven retraining are examined during inspections.
In regulated manufacturing, the organisation is part of the compliance architecture.
Regulatory, quality and data-integrity constraints
Manufacturing for the Indian market and manufacturing for export to highly regulated markets are different undertakings on the same site. Domestic requirements are administered by the central and state drug authorities, while export supply brings the inspection regime of each destination market. A site intended for both must be built and operated to the higher standard, with a single quality system rather than parallel ones.
Data integrity deserves separate attention because it is the most common source of serious findings in this sector globally. Audit trails, access control, review of electronic records, and the culture that determines whether an inconvenient result is investigated or repeated are all organisational choices. They should be designed at the start, with system configuration and governance, rather than corrected after an inspection.
Intellectual property in regulated manufacturing is protected mainly through process know-how, analytical methods, contractual arrangements and controlled technology transfer. Where a contract manufacturer is used, the technology-transfer package and the boundaries around it deserve as much attention as the commercial terms.
This page is manufacturing strategy, not regulatory or legal advice, and it deliberately offers no regulatory conclusions. Classification, licensing, approval pathways and inspection requirements must be confirmed with qualified regulatory advisers and current requirements for the specific product and market.
Setup, validation and approval: the sequence that governs the calendar
The construction schedule is rarely the constraint. The qualification and approval chain is.
- 01
Design qualification against the target market
Facility class, flows, segregation, utilities and monitoring are fixed at design. Changing them later means re-qualification.
- 02
Construction and utility systems
Water systems, HVAC, compressed gases and environmental controls are qualification-critical utilities, not building services.
- 03
Installation, operational and performance qualification
Sequential equipment qualification with documented protocols and evidence; this is where documentation discipline first becomes visible.
- 04
Technology and analytical method transfer
Process transfer, method transfer and comparability work, each with its own calendar and its own failure modes.
- 05
Validation batches and stability
Validation batches and stability data are time-bound and cannot be compressed; they sit directly on the critical path to approval.
- 06
Regulatory submission, inspection and approval
Filing, review, inspection and response cycles vary by market. Plan working capital for the interval between mechanical completion and approved supply.
Commercial commitments should be dated from approval, never from commissioning.
Evidence and classification
Published structures separated from NirjiX judgement, with regulatory conclusions deliberately excluded.
Reference period: Policy and programme structures as published up to the review date shown on this page.
- Fact
India operates Production Linked Incentive schemes covering pharmaceutical product categories and specified medical device segments.
Scheme guidelines are published by the Department of Pharmaceuticals and define categories, investment thresholds and production conditions.
Source: Department of Pharmaceuticals
- Fact
India operates bulk drug park and medical device park programmes providing common infrastructure at designated locations.
Programme structures are published by the Department of Pharmaceuticals; the operational status of common facilities varies by park and should be verified directly.
- Fact
Drug and medical device manufacturing in India is licensed and inspected under the central drugs regulatory framework, with state licensing authorities involved.
Administered by the Central Drugs Standard Control Organisation together with state authorities. Requirements are product- and class-specific and change; confirm with qualified advisers.
Source: CDSCO
- NirjiX analysis
Quality-system governance, not technical capability, is the most common failure mode for foreign entrants in this sector.
Judgement based on NirjiX engagement experience in regulated manufacturing; it reflects observed patterns in oversight design, not an assessment of any specific company or regulator finding.
- Client-specific calculation
Validation timelines, transfer costs and site economics for a specific product.
Determined during an engagement against the product, target markets, facility class and filing footprint.
What would change the recommendation?
- Target market set — adding a highly regulated export market changes facility design, documentation and cost before it changes revenue.
- Product classification or regulatory pathway changes, which can move a project between facility classes entirely.
- Filing footprint of an existing product — a wide variation burden can make a site transfer uneconomic regardless of manufacturing cost.
- Availability of a credible partner with a clean compliance history, which can compress the path to approved supply substantially.
- Effluent, water and utility feasibility at the selected site, particularly for API and chemical processing.
- Parent-organisation capacity to govern a distant quality system, including the willingness to fund oversight properly.
- Sterilisation, testing and calibration capacity for device projects, which can constrain both location and ramp.
NirjiX view
The NirjiX view
We would validate the target-market set and the quality-governance model before evaluating a single site. Those two decisions determine facility class, documentation burden, staffing and cost, and they are frequently deferred because they feel like detail. They are not detail; they are the specification.
The most common investment-case mistake in this sector is dating the return from commissioning rather than from approval. The interval between a mechanically complete facility and approved commercial supply is real, financed and often long. A case that ignores it looks better than the project can ever be.
What should not be localised too early is a product whose approval is tied to an existing site with a wide filing footprint. The transfer cost — re-validation, stability, variations across markets, and the risk of supply interruption — regularly exceeds the manufacturing saving. New products and new capacity are far better candidates for an India site than transfers of mature ones.
What management teams underestimate is the ongoing cost of inspection readiness. It is not a project that ends at approval; it is a permanent operating discipline covering documentation, training, audit trails and deviation management. Under-funding it is the most reliable way to convert a good site into a remediation programme.
The signal that the operating model should change is a CDMO relationship in which your oversight burden approaches what it would cost to run the operation yourself, or in which capacity allocation repeatedly fails your launch calendar. At that point the partner is no longer providing the flexibility that justified the model.
Frequently asked executive questions
- What most affects whether India works for a pharma or device site?
- The markets the site will supply. That single decision sets facility class, documentation standard, validation burden, staffing and cost. A site built for domestic supply and later asked to serve a highly regulated export market usually needs substantial rework, so the target-market set should be fixed before design begins rather than discovered afterwards.
- Should we use a CDMO or build our own facility in India?
- Use a CDMO when speed to approved supply, variable volume or capital discipline dominate, and when a partner with a clean compliance history and relevant facility class is available. Build your own when the process is proprietary, volumes justify the fixed cost, and long-term control of the quality system matters. Either way your oversight obligation remains, so budget for it in both models.
- Which Indian states fit pharma and medical device manufacturing?
- For APIs and chemical-intensive processes, the Gujarat and Telangana belts combine effluent and utility infrastructure with an existing regulated base. For formulations, Telangana, Maharashtra and the established northern formulation clusters offer depth. For devices, Tamil Nadu and Maharashtra provide the engineering supply chain, with dedicated device parks worth evaluating where their common facilities are genuinely operational. Site-level effluent, water and utility feasibility should decide the final choice.
- When do incentives change the case in this sector?
- They change the ranking between otherwise viable options rather than rescuing a weak case. Scheme support is conditional on investment, production and timelines, and claims must reconcile with production and regulatory records. Where infrastructure-led support such as a park provides operational common utilities and effluent treatment, the practical value can exceed a cash incentive — but only if those facilities are actually running.
- Which functions should stay with global headquarters?
- Regulatory strategy, quality-system standards, product release policy and the design authority for the process usually remain global, while execution, day-to-day quality operations, engineering and supply chain sit locally. The boundary should be written down with escalation paths, because the ambiguity between global standards and local execution is where compliance problems typically originate.
- How long before an India site can supply approved product?
- The calendar is governed by design and construction, then qualification, then technology and method transfer, then validation batches and stability, then filing and inspection. Each stage has an external dependency and stability data in particular cannot be compressed. Plan the working capital for that entire interval and date commercial commitments from approval, not from commissioning.
Continue
Related intelligence
- HubManufacturing in IndiaThe pillar hub: structural case, eight decision dimensions and the journey from assessment to run-state.
- DecisionIndia manufacturing business caseLanded-cost logic, ramp assumptions, incentive treatment and the tests an investment committee applies.
- DecisionIndia manufacturing location strategyHow a state and a site are chosen on suppliers, utilities, logistics, talent and approval throughput.
- DecisionIndia manufacturing operating modelsGreenfield, brownfield, JV, acquisition and contract manufacturing compared on control, speed and exit.
- DecisionFactory setup in IndiaLand to commissioning: approvals, utilities, construction, equipment, qualification and ramp.
- DecisionIndia manufacturing incentivesCentral schemes, state packages and the conditions that decide what is actually realisable.
- ResearchIndia Manufacturing Decision Guide 2026The full decision sequence with evidence classification and a downloadable companion report.
- ResearchIndia Manufacturing Location Intelligence 2026State-by-state comparison of industrial ecosystems, logistics and approval performance.
- IndustryHealthcare and life sciences servicesHow NirjiX supports life-sciences clients across manufacturing, capability centres and AI adoption.
Explore
Connected guides
More AI decisions
- Semiconductor and Electronics Manufacturing in India
For most companies the answer is yes for assembly, test, packaging, components, PCB and systems manufacturing, and conditional for wafer fabrication.
- Automotive and EV Manufacturing in India
For components with real domestic or export demand, the answer is usually yes: India has supplier density, tooling and machining depth, an experienced automotive workforce an…
- Industrial Machinery and Engineered Products in India
Yes for most machinery manufacturers, but for a specific reason: India offers engineering and machining capability at a cost structure that suits engineered products, plus a…
Transparency
Sources and methodology
This page reflects the NirjiX India Manufacturing Decision Framework and the firm's engagement experience across manufacturing feasibility, incentive structuring, site selection and factory execution in India.
Policy references — Production Linked Incentive schemes, the India Semiconductor Mission, PM MITRA parks, PM Gati Shakti and state industrial policies — describe scheme structures as published by the relevant central and state authorities. Eligibility, quantum and disbursement conditions change; every figure used in an investment decision should be confirmed against the notification in force at the time of application.
No compensation, capex, rent or incentive-quantum figures are asserted as universal benchmarks. Those are engagement inputs, validated per sector, per state and per site.
This page describes published scheme and regulatory structures and NirjiX practitioner judgement. It deliberately states no regulatory conclusions, approval timelines or facility-cost benchmarks; those are product-, market- and site-specific and require qualified advice.
- Department of Pharmaceuticals — PLI and park schemes
- Central Drugs Standard Control Organisation (CDSCO)
- Central Pollution Control Board and state pollution control boards
- State pharmaceutical and life-science policies
Test your regulated manufacturing case for India
The India Manufacturing Opportunity Assessment examines strategic fit, product economics, location, incentives, supply chain, talent, governance and execution readiness across twelve domains, and returns a structured view of where a regulated project is exposed. The sector is pre-set when you start here.
The assessment is preliminary decision support and is not regulatory, legal or tax advice. Classification, licensing and approval requirements must be confirmed with qualified advisers.